These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 36786145)

  • 1. Targeting SHP2 reverses BRAF inhibitor tolerance in anaplastic thyroid carcinoma.
    Tang T; Zhou J; Zhang LX; Yang G; Li WN; Zhu JJ; Xiong YF; Li JD
    Anticancer Agents Med Chem; 2023 Feb; ():. PubMed ID: 36786145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early Combined SHP2 Targeting Reverses the Therapeutic Resistance of Vemurafenib in Thyroid Cancer.
    Ma W; Tian M; Hu L; Ruan X; Zhang W; Zheng X; Gao M
    J Cancer; 2023; 14(9):1592-1604. PubMed ID: 37325052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of dabrafenib and erlotinib combination treatment on anaplastic thyroid carcinoma.
    Choi YS; Kwon H; You MH; Kim TY; Kim WB; Shong YK; Jeon MJ; Kim WG
    Endocr Relat Cancer; 2022 May; 29(6):307-319. PubMed ID: 35343921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting SHP2 sensitizes differentiated thyroid carcinoma to the MEK inhibitor.
    Zhi J; Yi J; Hou X; Wang W; Yang W; Hu L; Huang J; Guo S; Ruan X; Gao M; Zheng X
    Am J Cancer Res; 2022; 12(1):247-264. PubMed ID: 35141016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Melatonin synergizes BRAF-targeting agent dabrafenib for the treatment of anaplastic thyroid cancer by inhibiting AKT/hTERT signalling.
    Liao Y; Gao Y; Chang A; Li Z; Wang H; Cao J; Gu W; Tang R
    J Cell Mol Med; 2020 Oct; 24(20):12119-12130. PubMed ID: 32935463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined PI3K and MAPK inhibition synergizes to suppress PDAC.
    Bye BA; Jack J; Pierce A; Walsh RM; Eades A; Chalise P; Olou A; VanSaun MN
    bioRxiv; 2023 Aug; ():. PubMed ID: 37645960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination
    Gunda V; Ghosh C; Hu J; Zhang L; Zhang YQ; Shen M; Kebebew E
    Thyroid; 2023 Oct; 33(10):1201-1214. PubMed ID: 37675898
    [No Abstract]   [Full Text] [Related]  

  • 8. Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers.
    Hao HX; Wang H; Liu C; Kovats S; Velazquez R; Lu H; Pant B; Shirley M; Meyer MJ; Pu M; Lim J; Fleming M; Alexander L; Farsidjani A; LaMarche MJ; Moody S; Silver SJ; Caponigro G; Stuart DD; Abrams TJ; Hammerman PS; Williams J; Engelman JA; Goldoni S; Mohseni M
    Mol Cancer Ther; 2019 Dec; 18(12):2368-2380. PubMed ID: 31439712
    [No Abstract]   [Full Text] [Related]  

  • 9. Case report: Complete response of an anaplastic thyroid carcinoma patient with
    Gui L; Zhu Y; Li X; He X; Ma T; Cai Y; Liu S
    Front Immunol; 2023; 14():1178682. PubMed ID: 37122752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models.
    Fedele C; Ran H; Diskin B; Wei W; Jen J; Geer MJ; Araki K; Ozerdem U; Simeone DM; Miller G; Neel BG; Tang KH
    Cancer Discov; 2018 Oct; 8(10):1237-1249. PubMed ID: 30045908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overriding Adaptive Resistance to Sorafenib Through Combination Therapy With Src Homology 2 Domain-Containing Phosphatase 2 Blockade in Hepatocellular Carcinoma.
    Leung CON; Tong M; Chung KPS; Zhou L; Che N; Tang KH; Ding J; Lau EYT; Ng IOL; Ma S; Lee TKW
    Hepatology; 2020 Jul; 72(1):155-168. PubMed ID: 31610028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth arrest by activated BRAF and MEK inhibition in human anaplastic thyroid cancer cells.
    Kurata K; Onoda N; Noda S; Kashiwagi S; Asano Y; Hirakawa K; Ohira M
    Int J Oncol; 2016 Dec; 49(6):2303-2308. PubMed ID: 27748799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic Suppression of FAK-AKT Signaling Overcomes Resistance to SHP2 Inhibition in Colorectal Carcinoma.
    Li Y; Yuan Y; Zhang F; Guo A; Cao F; Song M; Fu Y; Xu X; Shen H; Zheng S; Pan Y; Chang W
    Front Pharmacol; 2021; 12():739501. PubMed ID: 34790119
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Valencia-Sama I; Ladumor Y; Kee L; Adderley T; Christopher G; Robinson CM; Kano Y; Ohh M; Irwin MS
    Cancer Res; 2020 Aug; 80(16):3413-3423. PubMed ID: 32586982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions.
    King AJ; Arnone MR; Bleam MR; Moss KG; Yang J; Fedorowicz KE; Smitheman KN; Erhardt JA; Hughes-Earle A; Kane-Carson LS; Sinnamon RH; Qi H; Rheault TR; Uehling DE; Laquerre SG
    PLoS One; 2013; 8(7):e67583. PubMed ID: 23844038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete response of metastatic
    Lee SJ; Song SY; Kim MK; Na HG; Bae CH; Kim YD; Choi YS
    World J Clin Cases; 2023 Sep; 11(27):6664-6669. PubMed ID: 37900238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibiting ERK dimerization ameliorates BRAF-driven anaplastic thyroid cancer.
    Zaballos MA; Acuña-Ruiz A; Morante M; Riesco-Eizaguirre G; Crespo P; Santisteban P
    Cell Mol Life Sci; 2022 Sep; 79(9):504. PubMed ID: 36056964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer.
    McFadden DG; Vernon A; Santiago PM; Martinez-McFaline R; Bhutkar A; Crowley DM; McMahon M; Sadow PM; Jacks T
    Proc Natl Acad Sci U S A; 2014 Apr; 111(16):E1600-9. PubMed ID: 24711431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers.
    Liu Z; Hou P; Ji M; Guan H; Studeman K; Jensen K; Vasko V; El-Naggar AK; Xing M
    J Clin Endocrinol Metab; 2008 Aug; 93(8):3106-16. PubMed ID: 18492751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAFV600E/Mt to Vemurafenib.
    Jiao X; Zhang H; Xu X; Yu Y; Zhang H; Zhang J; Ning L; Hao F; Liu X; Niu M; Chen CT; Chen D; Zhang K
    Cell Physiol Biochem; 2018; 49(3):1143-1162. PubMed ID: 30196299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.